Literature DB >> 27698866

4-isothiocyanate-2, 2, 6, 6-tetramethyl piperidinooxyl inhibits angiogenesis by suppressing VEGFR2 and Tie2 phosphorylation.

Yuanyuan Liu1, Jing Gao2, Shuangsheng Huang2, Lamei Hu3, Zhiqiang Wang3, Zheyuan Wang4, Xiao Chen4, Xiaoyu Zhang3, Wenguang Li3.   

Abstract

Reactive oxygen species (ROS) are involved in the signaling pathway and are triggered by angiogenic factors, including vascular endothelial growth factor and angiopoietins. 4-isothiocyanate-2, 2, 6, 6-tetramethyl piperidinooxyl (4-ISO-Tempo) is one of the nitroxides that exhibits antioxidant activity. However, the anti-angiogenic effect of 4-ISO-Tempo remains unknown. The aim of this study was to investigate the effect of 4-ISO-Tempo on tumor proliferation and angiogenesis as well as its underlying mechanisms. Our results revealed that 4-ISO-Tempo significantly inhibited the viability of neoplastic and endothelial cells. Furthermore, the effective concentration of 4-ISO-Tempo on human microvascular endothelial cell 1 (HMEC-1) was lower than that on human lung adenocarcinoma A549 and human colon cancer SW620 cells. This suggested that endothelial cells were more sensitive to 4-ISO-Tempo than tumor cells. Furthermore, we demonstrated that 4-ISO-Tempo also suppressed secretion of matrix metalloproteinase (MMP)-2 and MMP-9, and migration and tube formation of HMEC-1 cells. The mechanism is attributed to the decreasing ROS generation and further phosphorylation of vascular endothelial growth factor receptor 2 and Tie2. Our findings suggest that 4-ISO-Tempo should be investigated for its usefulness in anti-angiogenesis therapies.

Entities:  

Keywords:  2; 4-isothiocyanate-2; 6; 6-tetramethyl piperidinooxyl; Tie2; angiogenesis; reactive oxygen species; vascular endothelial growth factor receptor 2

Year:  2016        PMID: 27698866      PMCID: PMC5038461          DOI: 10.3892/ol.2016.4948

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  34 in total

1.  Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.

Authors:  Josep Tabernero; Takayuki Yoshino; Allen Lee Cohn; Radka Obermannova; Gyorgy Bodoky; Rocio Garcia-Carbonero; Tudor-Eliade Ciuleanu; David C Portnoy; Eric Van Cutsem; Axel Grothey; Jana Prausová; Pilar Garcia-Alfonso; Kentaro Yamazaki; Philip R Clingan; Sara Lonardi; Tae Won Kim; Lorinda Simms; Shao-Chun Chang; Federico Nasroulah
Journal:  Lancet Oncol       Date:  2015-04-12       Impact factor: 41.316

2.  NADPH oxidase 4 mediates reactive oxygen species induction of CD146 dimerization in VEGF signal transduction.

Authors:  Jie Zhuang; Tianxia Jiang; Di Lu; Yongting Luo; Chaogu Zheng; Jing Feng; Dongling Yang; Chang Chen; Xiyun Yan
Journal:  Free Radic Biol Med       Date:  2010-04-18       Impact factor: 7.376

3.  Grateloupia longifolia polysaccharide inhibits angiogenesis by downregulating tissue factor expression in HMEC-1 endothelial cells.

Authors:  Chao Zhang; Fan Yang; Xiong-Wen Zhang; Shun-Chun Wang; Mei-Hong Li; Li-Ping Lin; Jian Ding
Journal:  Br J Pharmacol       Date:  2006-05-22       Impact factor: 8.739

Review 4.  Strategies for MMP inhibition in cancer: innovations for the post-trial era.

Authors:  Christopher Mark Overall; Carlos López-Otín
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

5.  Grape seed proanthocyanidins inhibit angiogenesis via the downregulation of both vascular endothelial growth factor and angiopoietin signaling.

Authors:  Shuangsheng Huang; Ninggang Yang; Yuanyuan Liu; Lamei Hu; Jin Zhao; Jing Gao; Yongquan Li; Caili Li; Xiaosu Zhang; Tao Huang
Journal:  Nutr Res       Date:  2012-07-05       Impact factor: 3.315

6.  Parthenolide exerts inhibitory effects on angiogenesis through the downregulation of VEGF/VEGFRs in colorectal cancer.

Authors:  Se-Lim Kim; Soo-Teik Lee; Kieu Thi Thu Trang; Seong Hun Kim; In Hee Kim; Seung Ok Lee; Dae Ghon Kim; Sang-Wook Kim
Journal:  Int J Mol Med       Date:  2014-02-25       Impact factor: 4.101

7.  Interleukin-8 as a macrophage-derived mediator of angiogenesis.

Authors:  A E Koch; P J Polverini; S L Kunkel; L A Harlow; L A DiPietro; V M Elner; S G Elner; R M Strieter
Journal:  Science       Date:  1992-12-11       Impact factor: 47.728

Review 8.  Tyrosine kinase inhibitors in cancer therapy.

Authors:  Srinivasan Madhusudan; Trivadi S Ganesan
Journal:  Clin Biochem       Date:  2004-07       Impact factor: 3.281

9.  Study of in vitro and in vivo effects of the piperidine nitroxide Tempol--a potential new therapeutic agent for gliomas.

Authors:  M B Gariboldi; R Ravizza; C Petterino; M Castagnaro; G Finocchiaro; E Monti
Journal:  Eur J Cancer       Date:  2003-04       Impact factor: 9.162

10.  High mobility group protein HMGI(Y) enhances tumor cell growth, invasion, and matrix metalloproteinase-2 expression in prostate cancer cells.

Authors:  Natsuki Takaha; Linda M S Resar; Don Vindivich; Donald S Coffey
Journal:  Prostate       Date:  2004-07-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.